NIKKEI 225
26,430.16 -374.44 (-1.40%) HANG SENG
22,047.11 +50.22 (+0.23%) CRUDE OIL
109.94 +0.16 (+0.15%) GOLD FUTURES
1,816.80 -0.70 (-0.04%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,486.23 -340.92 (-2.03%)
LENSAR, Inc. (LNSR)
| Previous close | 6.20 |
| Open | 6.36 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's range | 6.33 - 6.50 |
| 52-week range | 5.50 - 8.98 |
| Volume | |
| Avg. volume | 14,383 |
| Market cap | 70.303M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.20 |
| Earnings date | 09 May 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.00 |
- Business Wire
LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System
ORLANDO, Fla., June 13, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration ("FDA") 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System ("ALLY" or "ALLY System"). ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract sur
- Simply Wall St.
Shareholders in LENSAR (NASDAQ:LNSR) are in the red if they invested a year ago
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
- Business Wire
LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla., May 09, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives.
